文献速递肾小球疾病

Cemdisiran 治疗成人 IgA 肾病的 2 期随机对照试验

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-01-15

第 32 周时,cemdisiran 组 24 小时 UPCR 较基线变化经安慰剂校正后为 -37.4%,点尿 UPCR 校正变化为 -45.8%,血清 C5 下降 98.7%,总体耐受良好。

要点

  • Cemdisiran 600 mg 每 4 周皮下注射使 24 小时 UPCR 经安慰剂校正下降 37.4%。
  • 点尿 UPCR 经安慰剂校正下降 45.8%,与 24 小时尿结果一致。
  • 血清 C5 平均水平下降 98.7%,注射部位反应最常见(41%)。

核心结论

  • Cemdisiran 治疗使成人 IgA 肾病患者第 32 周蛋白尿下降,且耐受良好。

研究设计与样本

  • 2 期、36 周、双盲、随机对照研究,纳入尿蛋白≥1 g/24h 的成人 IgA 肾病患者,按 2:1 随机接受皮下 cemdisiran 600 mg 或安慰剂每 4 周一次,联合标准治疗。
  • 主要终点为第 32 周 24 小时尿采集测定的 UPCR 较基线百分比变化。

主要发现

  • 第 32 周时,cemdisiran 组 24 小时 UPCR 较基线的安慰剂校正几何均值变化为 -37.4%(cemdisiran 校正几何均值比 0.69,SEM 0.10)。
  • 第 32 周时,点尿 UPCR 的安慰剂校正变化为 -45.8%(cemdisiran 校正几何均值比 0.73,SEM 0.11),与 24 小时 UPCR 结果一致。
  • 第 32 周时,血清 C5 水平较基线平均(SD)变化在 cemdisiran 组为 -98.7%(1.2),安慰剂组为 25.2%(57.7)。
  • 36 周内多数不良事件为轻中度且短暂,cemdisiran 治疗后最常见不良事件为注射部位反应(41%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgA nephropathy is the most common primary GN. Clinical features of IgA nephropathy include proteinuria, which is the strongest known surrogate of progression to kidney failure. Complement pathway activation is a critical driver of inflammation and tissue injury in IgA nephropathy. Cemdisiran is an investigational RNA interference therapeutic that suppresses hepatic production of complement component 5 (C5), thereby potentially reducing proteinuria in IgA nephropathy. We evaluated the efficacy and safety of cemdisiran in adult patients with IgA nephropathy at high risk of kidney disease progression. METHODS: In this phase 2, 36-week, double-blind study, adult patients with IgA nephropathy and urine protein ≥1 g/24 hours were randomized (2:1) to subcutaneous cemdisiran 600 mg or placebo every 4 weeks in combination with the standard of care. The primary end point was percentage change from baseline at week 32 in urine protein-to-creatinine ratio (UPCR) measured by 24-hour urine collection. Additional end points included change from baseline in UPCR measured by spot urine, serum C5 level, and safety assessments. RESULTS: Thirty-one patients were randomized (cemdisiran, N =22; placebo, N =9). Cemdisiran-treated patients had a placebo-adjusted geometric mean change in 24-hour UPCR of -37.4% (cemdisiran-adjusted geometric mean ratio to baseline [SEM], 0.69 [0.10]) at week 32. Spot UPCR was consistent with 24-hour UPCR placebo-adjusted change of -45.8% (cemdisiran-adjusted geometric mean ratio to baseline [SEM], 0.73 [0.11]). Mean (SD) change in serum C5 level from baseline at week 32 was -98.7% (1.2) with cemdisiran and 25.2% (57.7) with placebo. Over 36 weeks, most adverse events were mild or moderate and transient; the most common adverse event after cemdisiran treatment was injection-site reaction (41%). CONCLUSIONS: These findings indicate that treatment with cemdisiran resulted in a reduction of proteinuria at week 32 and was well tolerated.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Barratt J, Liew A, Yeo SC, et al. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2024. PMID: 38214599. doi:10.2215/CJN.0000000000000384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。